1. ICON plc Goldman Sachs Mid-Cap Conference March 11 th 2005 ICON plc Goldman Sachs Mid-Cap Conference March 11 th 2005 www.iconclinical.com

2. Overview www.iconclinical.com Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward Looking Statements

3. Snapshot www.iconclinical.com Fourth largest Clinical CRO in the world Quintiles PPD Parexel ICON Dedicated team model and quality ethos differentiates ICON from competitors Over $300m in Net Revenues and approx 2700 staff 37 offices in 23 countries on five continents

4. Offices: US www.iconclinical.com Chicago Houston Nashville Tampa San Francisco Irvine Baltimore Raleigh-Durham New York City Long Island Philadelphia Delaware Doylestown

5. Offices: Europe and Middle East www.iconclinical.com Riga Amsterdam Frankfurt Marlow Stockholm Dublin Manchester Eastleigh Paris Tel Aviv Moscow Barcelona Budapest

6. Offices: ROW www.iconclinical.com Sydney Buenos Aires Johannesburg Taiwan Seoul Bangkok Singapore Chennai Tokyo Hong Kong Montreal

7. www.iconclinical.com Current Services in Drug Development Pre-clinicalPhase IPhase IIPhase IIILaunchPhase IV 6% Strategic Drug Development and Regulatory Consulting (US & EU) 5% Phase I 8% Central lab (Global) 16% Data Management & Statistical Consulting (Global) 57% Trial Management & Monitoring (Global) 2.5% Contract Staffing (US) 2.5% Central Imaging Lab (US & EU) 3% IVRS (Global)

8. ICON plc Market Dynamics ICON plc Market Dynamics www.iconclinical.com

9. Three Elements Supporting Growth www.iconclinical.com Growth in Underlying spending (1) Total 2005 R&D spend estimated at > $82bn; 10% growth forecast to continue Total 2005 Development Spend estimated at >$54bn; 11% growth forecast Continued growth in outsourcing (1) Industry estimated to outsource approximately 27% of development and growing by 1% per annum. Market growth estimated at 14% Pharma reducing supplier numbers Fewer CROs servicing Large Pharma = Market share gains for Global and multi-service CROs (1) Source Jeffries & Co.

10. Strong Market Environment Preferred Providers Improving Pipelines Biotech / Specialty Companies Regulatory Environment www.iconclinical.com

11. RFP Volume / Value Trends – US Last 4 Quarterswww.iconclinical.com RFP Value GrowthRFP Volume Growth

12. Bio-Tech, Mid-Sized and Japanese companies are now significant outsourcers www.iconclinical.com Biotech and specialty companies account for a growing percentage of projects in development: 55% of 2002 Clinical trials are derived from biotech companies. Currently estimated to be more compounds in development in biotech/specialty than in all of Top 20 Pharma ICON’s sales to non Top 20 pharma companies have been rising strongly: 21% 26% 35% 39% 40% 42% Scope for Growth

13. www.iconclinical.com ICON Gross Business Wins Last 9 Quarters

14. Total Backlog $Millions

15. www.iconclinical.com ICON plc Financial Performance (Fiscal Years ending May 31)

16. www.iconclinical.com Net Revenue CAGR of 38% over last 5 Years CAGR 38%

17. www.iconclinical.com CAGR =35% 7 Years of Earnings Per Share Growth….

18. www.iconclinical.com …However, ICON Has Traditionally Experienced Low Cancellation Rates but in Q1 05…… Cancellations as % of Opening Backlog $46m cancellations inc. 2 major projects

19. www.iconclinical.com Quarterly Revenue and Operating Profit

20. www.iconclinical.com Quarterly EPS FY2000FY2001 FY2005FY2004FY2003FY2002

21. Summary Balance Sheet and Cashflow ($ millions) www.iconclinical.com Nov 30, 2004 (Half Year) May 31, 2004 (Year) Cash and cash equivalents$71.0$78.8 Total assets$370.4$335.3 Total debt$10.0$0.0 Shareholder’s equity$236.3$216.8 Cashflow from operations($2.0)$43.6 Capital expenditures$7.5$13.1 Fully diluted shares outstanding14.113.7

22. Current Issues / Strategic Development www.iconclinical.com

23. Current Tactical Issues Recovery from Exceptional Cancellation Quarter to Restore Growth Net Wins $120m in Nov Qtr Good net wins again expected for Feb quarter www.iconclinical.com Capitalise on Lab Investments and Sales Success to Eliminate Losses Continue Sales Success Add more major clients Develop technological base

24. www.iconclinical.com ICON LABS Net New Business Wins Net Business Wins Book to Bill Ratio Average Book-to-Bill 1.35

25. Strategic Mission To continue to develop our business as a global, full service, clinically focused CRO, and to leverage the synergies between our multiple services.

26. Use “Full Service” to Leverage Client Relationships and Capture more of the Spend Strategic Product Development / Consulting 6% Strategic Product Development / Consulting 6% Clinical Trial Management Phase II – IV 57% Clinical Trial Management Phase II – IV 57% Phase I 5% Phase I 5% Central Laboratory 8% Central Laboratory 8% IVRS 2.5% IVRS 2.5% Contract Staff 3% Contract Staff 3% Central Imaging Lab 2.5% Central Imaging Lab 2.5% Data Management & Biostatistics 16% Data Management & Biostatistics 16%

27. Current Strategic Initiatives Investing in Operations in Japan Creation of Data Management Operation in India Partnership with Medidata Solutions in EDC Developing specialised Phase IV Division New IT in 2005 to enhance efficiency New Trial Management and Project Collaboration Systems New Document Management System New eLearning System

28. Current Acquisition / Investment Focus Central Labs to increase scale Additional Central Imaging Expertise to broaden offering Phase I in US to compliment EU facility Analytical Labs to compliment EU facility New Expertise in any of core areas to add scale / unique expertise

29. Organic Get more business from current clients Add new clients Sell more new services - IVRS/Lab/Consulting/Phase I Expand global presence Increase therapeutic experience Acquisitions Add new services and broaden existing ones Goal To be the best Future Development www.iconclinical.com